gsk arixtra sales

GSK US sales for the quarter just under $US26m (16m pounds)

http://www.gsk.com/investors/reports/q12012/q12012_statutory.pdf

According to their report:

"Arixtra sales declined 34% as a result of generic
competition in the US which began in Q3 2011."
(see http://www.gsk.com/investors/reports/q12012/q12012.pdf)

Can anyone estimate whether this is below or on par with expectations based on their dropping market share expectations?

I cannot find any ref to the Apotex Fonda (AG) figures - surely they should be incorporated into the figures somewhere - maybe they are part of the above?

I'm keenly awaiting the DR figures!!!